ERBB2 and breast cancer: However, in the pre-SCB implementation period, there were statistically significant fewer patients with Luminal-B (25.3% vs. 29.6%, p = 0.02) and HER2-luminal (7.9% vs. 12.9%, p = 0.02) breast cancer subtypes (Table 1).